As Home | Add Favorite   
Current Position:  Home > News Center > Academic News Academic News

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

From:

http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

Description

Theglobal peptide therapeutics market report provides detailed analysis, marketsize, and forecast for therapeutic peptides approved for various indications.The market is studied from four major perspectives: applications, route ofadministration, marketing status, and geography. Application segments of theglobal peptide therapeutics market have been further sub-segmented by majorbranded peptide drugs approved by regulatory authorities across the globe.Various applications considered in the report include metabolic disorders,hematological disorders, cancer, cardiovascular disorders, central nervoussystem disorders, infection, gastrointestinal disorders, respiratory disorders,acromegaly, and others. Market size and forecast for leading drugs such as Angiomax,Copaxone, Forteo, Sandostatin, Velcade, Victoza, and Zoladex has been includedalong with in-depth market analysis. Segmentation by marketing status explainsthe impact of generic drugs on the overall peptide therapeutics market.Further, market segmentation of peptide drugs by route of administrationprovides quantitative insights into the growing demand for convenient methodsfor peptide drug administration. Details on peptide drug approvals, patentexpiry, mergers, acquisitions, strategic agreements, disease prevalence andother major events have been included in respective market segments.

 

Theglobal peptide therapeutics market report provides market estimation andforecast for more than fifteen branded peptide drugs in the market. Further,the market is also segmented by major geographical regions, which include NorthAmerica, Europe, Asia Pacific and Rest of the World. A list of pipeline drugshas also been provided in the report. This list includes potential peptidedrugs in phases I, II, and III of clinical development. 

 

Emergingtrends in global peptide API production, such as development of new peptide APIproduction technologies and strategic agreements in peptide API production havebeen discussed. The report also profiles key peptide API suppliers. An overviewof regulatory policies has also been provided in the global peptidetherapeutics market report. Based on our in-depth analysis and comprehensivemarket study, key factors driving and restraining the market have beendiscussed. A detailed event impact analysis considers regulatory approvals,patent expiry of major drugs, drug recalls and other factors in the peptidetherapeutics market.  The research study also incorporates the competitivescenario in these regions, where market share of seven major players in 2013has also been provided. Relevant recommendations have been provided for newentrants as well as existing market players to help them establish a strongpresence in the market and increase their share. Fifteen major players havebeen profiled which include Amgen, Inc., AstraZeneca plc, Bachem Holding AG,CordenPharma International GmbH, Eli Lilly & Co., Ipsen S.A., Lonza, Inc.,Merck & Co., Novartis AG, Novo Nordisk A/S, PolyPeptide Group, RocheHoldings AG, Sanofi, Takeda Pharmaceutical Company Limited, and TevaPharmaceutical Industries Limited. The 104 pages global peptide therapeuticsmarket report includes 30 figures and charts, and 14 tables. 

 

Marketsize and forecast in terms of USD million for each segment in the globalpeptide therapeutics market has been provided for the period 2012 to 2020,considering 2012 and 2013 as the base years. The report also provides thecompounded annual growth rate (CAGR %) for each market segment for the forecastperiod 2014 to 2020. The peptide therapeutics market has been estimated using abottom-up approach, where market size estimates for each drug have beensummed-up to arrive at the total market size. Market forecasts have beenderived considering the effect of generic drug approvals, drug recalls, diseaseprevalence, patent term extension, box warning and various other factors.Inputs from industry experts and key opinion leaders have validated and furtherrefined our market estimates.   

 

Theglobal peptide therapeutics market has been segmented as below:

·        Global Peptide TherapeuticsMarket, by Application

o    Cancer

§  Zoladex(goserelin)

§  Velcade(bortezomib)

§  Lupron/Enantone/ Eligard (leuprorelin)

§  Others

o    Cardiovascular

§  Angiomax(bivalirudin)

§  Integrilin(eptifibatide)

o    CentralNervous System

§  Copaxone(glatiramer)

o    MetabolicDisorders

§  Victoza(liraglutide)

§  Byetta(exenatide)

§  Others

o    Infection

§  Incivek(telaprevir)

§  Victrelis(boceprevir)

o    HematologicalDisorders

§  Firazyr(icatibant)

§  Kalbitor(ecallantide)

o    GastrointestinalDisorders

§  Gattex(teduglutide)

§  Linzess(linaclotide)

o    RespiratoryDisorders

o    Acromegaly

o    OtherApplications

·        Global Peptide TherapeuticsMarket, by Route of Administration

o    Parenteral

o    Oral

·        Global Peptide TherapeuticsMarket, by Marketing Status

o    Branded

o    Generic

·        Global Peptide TherapeuticsMarket, by Geography

o    NorthAmerica

o    Europe

o    AsiaPacific

o    Restof the World